Renal artery stenosis may cause or exacerbate hypertension and renal failure. Percutaneous transluminal renal artery stent placement, increasingly the firstline therapy for ostial atherosclerotic renal artery stenosis, can be complicated by instent restenosis weeks to months after the procedure. There is currently no consensus for the treatment of in-stent restenosis. Sirolimus-eluting stents have been shown to be effective to treat in-stent restenosis in the coronary circulation. We report a case of sustained 24-month patency after repair of recurrent renal artery instent restenosis with use of a sirolimus-eluting stent.
Introduction
Renal artery stenosis, most frequently due to atherosclerosis, may cause or aggravate hypertension and can lead to impaired renal function. 1 In patients with peripheral arterial disease, renal artery stenosis has been identified as an independent predictor of mortality. 2 Percutaneous transluminal renal artery stenting (PTRAS) has become the preferred method of treating ostial atherosclerotic renal artery stenosis. Multiple studies have found PTRAS to be both functionally and technically superior to conventional balloon angioplasty. 3, 4 One potential complication of PTRAS is in-stent restenosis. A recent literature review found rates of restenosis at 6 months postprocedure ranging from 6% to 30%. 4 Restenosis after stent implantation is more likely in patients with a renal artery diameter smaller than 6 mm, if the stent is not appropriately sized or fully expanded, or if the ostium of the renal artery is not adequately covered. However, in-stent restenosis (ISR) can occasionally occur in the absence of these aforementioned factors. [4] [5] [6] The optimal treatment of renal artery restenosis that has failed angioplasty or placement of a second stent is poorly defined. The problem of in-stent restenosis has been significantly reduced in the coronary circulation with the use of drug-eluting stents. 7 There is no consensus on the best method to treat in-stent restenosis of the renal artery. We present a case of renal artery restenosis that was effectively treated with a sirolimus-eluting stent. Three previous revascularizations had failed to keep the renal artery patent for more than 9 months.
Case report
A 78-year-old male with previous history of type A aortic dissection treated by open surgical ascending and descending thoracic aortic repair and infrarenal abdominal aortic aneurysm treated by endovascular repair presented with poorly controlled hypertension on four antihypertensive agents and chronic kidney disease (serum creatinine 1.9 mg/dl, estimated glomerular filtration rate 42 ml/min/ 1.73 m 2 ). The patient had been previously identified to have a single functioning left kidney. He initially underwent left renal artery stenting with a 5.0 × 15 mm bare metal stent (Genesis; Cordis Endovascular, Miami Lakes, FL, USA) with improvement in his blood pressure control.
Seven months later, his blood pressure again became difficult to manage. Duplex ultrasonography demonstrated severe in-stent restenosis, with a peak systolic velocity (PSV) of 434 cm/s. The patient underwent repeat intervention with balloon angioplasty and ultimately repeat stenting with a 6.0 × 18 mm balloon expandable stent (Cordis Endovascular). This stent was dilated to 6.5 mm, reducing the trans-ostial gradient to less than 10 mmHg and again improved control of the patient's hypertension followed.
Approximately 6 months later, the hypertension again became poorly controlled and the diagnosis of recurrent ISR was confirmed by duplex ultrasonography (PSV 541 cm/s). At this time, re-intervention was performed with a 6 mm angioplasty balloon (Boston Scientific, Natick, MA, USA) with successful resolution of the trans-lesional gradient to < 10 mmHg.
The patient's hypertension again improved initially but once again worsened 9 months later. Duplex ultrasound again confirmed ISR (PSV 455 cm/s) and the patient again underwent reintervention. At this presentation, the patient received intravenous heparin to reach an activated clotting time > 300 s. The left renal artery was engaged with a 6 Fr RDC guide catheter (Boston Scientific), and the stenosis was crossed with a 0.014 inch XS Stabilizer wire (Cordis Endovascular). Given the fact that he had developed in-stent restenosis twice following bare-metal stent implantation and once following angioplasty alone, the decision was made to treat the ISR with a sirolimus-eluting stent. The stenotic segment was stented with a 3.5 × 23 mm sirolimus-eluting stent (Cypher; Cordis Endovascular) deployed at 15 atm and post-dilated with a 4.0 × 20 mm Aviator balloon (Cordis Endovascular) to 15 atm. The final angiogram demonstrated good stent apposition and size, and the angiogram revealed no residual stenosis. At the completion of the procedure, the trans-lesional systolic gradient was 4 mmHg (Figure 1 ).
Since this intervention, the patient's hypertension has been well controlled. At the 24-month followup, the patient has no evidence of restenosis at duplex ultrasonography (PSV 193 cm/s). The patient currently has stable renal function, with serum creatinine of 1.9 mg/dl.
Discussion
In-stent restenosis remains a significant problem after PTRAS with bare metal stents. 4 Methods of treating renal artery ISR include angioplasty, cut-ting balloon angioplasty, vascular brachytherapy, repeat stenting, placement of a drug-eluting stent, and surgical bypass. 8 Historically the most common method of treating ISR, angioplasty, has been associated with variable outcomes. Bax et al. reported a 25% rate of restenosis after angioplasty for ISR, while studies preceding this had reported rates between 22% and 54% at 6 months. 9 Stoeteknuel-Friedli et al. reported 20% restenosis at the 1-year follow-up in a series of 10 patients receiving angioplasty accompanied by 192 Ir brachytherapy. 10 Zeller et al. concurrently published a series of data following stent-in-stent treatment of ISR as well as a study evaluating patency following two or more re-interventions after renal artery stent placement. 8, 11 Their findings discourage use of cutting balloons in treatment of ISR and show relatively favorable outcomes with balloon angioplasty alone as with repeat stenting. Zeller et al. also reported encouraging initial results with the use of drug-eluting stents (DES). 8, 11 The treatment of ISR with DES in coronary arteries is yielding promising results 12 ; and a recent randomized trial found that the DES was superior to angioplasty with intravascular brachytherapy in the treatment of coronary artery ISR. 13 There have been few other reports of the use of a DES in treating renal artery ISR. 14 Currently the only finished study on drug-eluting stents in atherosclerotic ostial renal artery stenosis (RAS) is the GREAT trial, which examined sirolimus-eluting stents compared to bare metal stents in the treatment of atherosclerotic ostial renal artery stenosis. 15 In-stent percent diameter stenosis, binary restenosis rates, late lumen loss and the repeat revascularization procedures were all lower in the DES group, although the difference with the bare metal stent group was not statistically significant. No adverse effect on renal function was observed in the DES group, which was a theoretical concern with downstream drug elution into the renal parenchyma. The sirolimus-eluting stent used in the GREAT study is currently not commercially available. At present, DES are manufactured solely for use in coronary vessels and range in diameter from 2.5 mm to 4.0 mm and the integrity of drugeluting polymer is lost with overexpansion past approximately 4.25 mm in diameter. 14 The perceived benefit of mild to moderate post-dilatation led to the choice of the final deployment diameter in our patient. This represents a major practical limitation for DES use in the renals that are typically 5-7 mm in diameter. 16 Fortunately, in-stent restenosis tends to occur less often in larger diameter vessels. Multiple studies have linked a small renal artery diameter with increased rates of restenosis, leading to the suggestion that DES may be useful in primary PTRAS of small vessels as well as in the treatment of in-stent restenosis. 5, 8, 11 For example, in one study of renal artery stenting, vessels with a diameter smaller than 4.5 mm had a restenosis rate of 36.0%, compared with a 6.5% rate of restenosis in vessels with diameters greater than 6.0 mm. 17 Another limitation is the higher cost of DES and the post-procedure need for long-term antiplatelet therapy with aspirin and clopidogrel.
Developing restenosis 7 months after his initial PTRAS, the patient we describe underwent placement of a second bare metal stent, then angioplasty, but restenosis again developed between 6 and 9 months after each intervention. A third and final intervention to-date has been placement of a sirolimus-eluting stent, which remains free from restenosis at 24 months. In small renal arteries, overdilatation of coronary DES may be a way to prevent recurrent restenosis.
